Journals / Eskisehir Medical Journal / 2021 / Cilt: 2 - Sayı: 1

Drug and Food Interactions with Warfarin

Varfarin ile Oluşan İlaç ve Besin Etkileşimleri

Pages
43–47
Publication Date
2021-03-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The purpose of this review is to increase the knowledge level of warfarin on drug and food interactions.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Warfarin, which is frequently used in the treatment of thromboembolism, is a potent anticoagulant.
📊
Key Findings & Data:Due to drug and food interactions, the effectiveness of treatment decreases or spontaneous bleeding occurs.
💡
Conclusion & Impact:The purpose of this review is to increase the knowledge level of warfarin on drug and food interactions.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Varfarin · ilaç etkileşimleri · besin-ilaç etkileşimleri

Abstract

Warfarin, which is frequently used in the treatment of thromboembolism, is a potent anticoagulant. It is a narrow therapeutic index drug and there is a risk of bleeding when the therapeutic dose is exceeded. It interacts with many drugs and foods. Due to drug and food interactions, the effectiveness of treatment decreases or spontaneous bleeding occurs. Although drug interactions constitute a small part of adverse drug reactions, they are important because they cause predictable and preventable mortality and morbidity. Prevention of drug interactions provides shortened hospital stay, reduced readmission rate, and reduced treatment costs. Examining the treatment applied to patients in terms of drug interactions increases the effectiveness and reliability of the treatment. The purpose of this review is to increase the knowledge level of warfarin on drug and food interactions.

Özet

Tromboembolizm tedavisinde sıklıkla kullanılan varfarin, güçlü bir antikoagülandır. Dar terapötik indeksli bir ilaçtır ve terapötik doz aşıldığında kanama riski oluşmaktadır. Birçok ilaç ve besin ile etkileşimi söz konusudur. İlaç ve besin etkileşimleri sebebi ile tedavi etkinliği azalmakta veya spontan kanamalar meydana gelmektedir. İlaç etkileşimleri advers ilaç reaksiyonlarının küçük bir kısmını oluşturmasına rağmen, öngörülebilir ve önlenebilir mortalite ve morbidite sebebi olması nedeni ile önemlidir. İlaç etkileşimlerinin önlenmesi hastanede kalış süresinin kısalmasını, yeniden başvuru oranının azalmasını ve tedavi maliyetlerinin azalmasını sağlar. Hastalara uygulanan tedavinin ilaç etkileşimleri açısından incelenmesi, tedavi etkinliğini ve güvenilirliğini artırmaktadır. Bu derlemenin amacı, varfarinin ilaç ve besin etkileşimleri hakkında bilgi düzeyinin artırılmasıdır.

🔖

Cite This Article

GÜRCÜ, S., AVCI, E., KUTSAL, Ö. (2021). Drug and Food Interactions with Warfarin. Eskisehir Medical Journal, Cilt: 2 - Sayı: 1, 43–47. https://ajindex.com/articles/851874

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Stahmann MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. V. Identification and synthesis of the hemorrhagic agent. J Biol Chem. 1941; 138: 513-27
  2. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001927
  3. Hirsh J, Dalen J, Anderson D, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001; 119(1 Suppl):8-21
  4. Wells PS, Holbrook AM, Crowther NR, et al. Interactions of warfarin with drugs and food. Ann Intern Med. 1994 Nov 1;121(9):676-83
  5. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002 Sep;36(9):1331-6
  6. Jonker DM, Visser SA, van der Graaf PH, et al. Towards a mechanism-based analysis of pharmacodynamic drug–drug interactions in vivo. Pharmacol Ther. 2005 Apr;106(1):1-18
  7. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003 Apr 2;289(13):1652-8
  8. Tanaka E. Clinically important pharmacokinetic drug–drug interactions: Role of cytochrome P450 enzymes. J Clin Pharm Ther. 1998 Dec;23(6):403-16
  9. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs. 1983 Jun;25(6):610-20
  10. Wittkowsky AK. Warfarin and other coumarin derivatives: pharmacokinetics, pharmacodynamics, and drug interactions. Semin Vasc Med. 2003 Aug;3(3):221-30
  11. Tadros R, Shakib S. Warfarin--indications, risks and drug interactions. Aust Fam Physician. 2010 Jul;39(7):476-9
  12. Fitzmaurice DA, Blann AD, Lip GY. Bleeding risks of antithrombotic therapy. BMJ. 2002 Oct 12;325(7368):828-31
  13. Delaney JA, Opatrny L, Brophy JM, et al. Drug–drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007 Aug 14;177(4):347-51
  14. Marnett LJ, Rowlinson SW, Goodwin DC, et al. Arachidonic acid oxygenation by COX-1 and COX-2 mechanisms of catalysis and inhibition. J Biol Chem. 1999 Aug 13;274(33):22903-6
  15. Chan TY. Adverse interactions between warfarin and nonsteroidal antiinflammatory drugs: mechanisms, clinical significance, and avoidance. Ann Pharmacother. 1995 Dec;29(12):1274-83
  16. Musumba C, Pritchard DM, Pirmohamed M. Review article: cellular and molecular mechanisms of NSAID-induced peptic ulcers. Aliment Pharmacol T